RxDoctor Payments Data

Jon Nichols, MD

Gastroenterology · Overland Park, KSNPI 1154391654

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.2% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 49.3% of the total.

$2,606in general payments, 2019–2025

Across 151 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$376
  • Braintree Laboratories, Inc.$180
  • Novo Nordisk$101
  • Ardelyx, Inc.$100
  • Takeda Pharmaceuticals U.S.A., Inc.$77
  • plus $489 from 14 others

What the payments were for

  • Food & beverage$2,42993%
  • Education$171%
  • Gifts$1606%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,606 in reported general payments places this provider in the 55th percentile of 98 gastroenterology providers in Kansas.

See all gastroenterology providers in Kansas

Medicare billing

Part B allowed, 2024
$126,754
Medicare patients
535
Services billed
2,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates418$28,005
LinzessLinaclotide19$17,917
Mesalamine35$6,900
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,791
Budesonide DrBudesonide11$1,365
Pantoprazole Sodium149$1,131
Colestipol Hcl11$654
Omeprazole61$594
Famotidine31$346
Spironolactone20$242
Sucralfate11$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,284$17,91719 claims
Braintree Laboratories, Inc.Sutab$180$1,79111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 98 gastroenterology providers in Kansas.

Other gastroenterology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →